参芎葡萄糖注射液联合厄贝沙坦治疗糖尿病肾病的临床研究
|
摘要
目的研究参芎葡萄糖注射液联合厄贝沙坦片治疗糖尿病肾病的临床疗效。方法选取2015年3月—2017年3月海南省第三人民医院接收的120例糖尿病肾病患者作为研究对象,随机将所有患者分为对照组和治疗组,每组各60例。对照组患者口服厄贝沙坦片75 mg/次,2次/d;治疗组在对照组治疗的基础上静脉滴注参芎葡萄糖注射液,200 mL/次,1次/d。两组患者均持续治疗30 d。观察两组患者临床疗效,比较两组患者在治疗前后的空腹血糖(FBG)、糖化血红蛋白(HbAlc)、尿白蛋白排泄率(UAER)、尿α1微球蛋白(α_1-MG)、血清肌酐(Scr)、尿素氮(BUN)、尿酸(UA)水平。结果治疗后,对照组和治疗组的总有效率分别为88.33%、96.67%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者FBG和HbAlc水平均比治疗前显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组患者血糖指标水平明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者的UAER和α_1-MG水平均显著下降,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组UAER和α_1-MG水平均明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者UA和治疗前相比显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组UA显著低于对照组,两组比较差异具有统计学意义(P<0.05)。结论参芎葡萄糖注射液联合厄贝沙坦片治疗早期糖尿病肾病具有较好的临床疗效,改善血糖和肾功能指标,具有一定的临床推广应用价值。
Objective To study the clinical effect of Salivae Miltiorrhizae Liguspyragine Hydrochloride and Glucose Injection combined with Irbesartan Tablets in treatment of diabetic nephropathy. Methods Patients(120 cases) with diabetic nephropathy in the Third People's Hospital of Hainan Province from March 2015 to March 2017 were randomly divided into control group and treatment group, and each group had 60 cases. Patients in the control group were po administered with Irbesartan Tablets, 75 mg/time, twice daily. Patients in the treatment group were iv administered with Salivae Miltiorrhizae Liguspyragine Hydrochloride and Glucose Injection on the basis of the control group, 200 mL/time, once daily. Patients in two groups were treated for 30 d. After treatment, the clinical efficacy was evaluated, and the levels FBG, HbAlc, UAER, α_1-MG, Scr, BUN, and UA in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 88.33% and 96.67%, respectively, and there were differences between two groups(P < 0.05). After treatment, FBG and HbAlc levels were significantly decreased in two groups, and there were differences in the same group(P < 0.05). After treatment, the blood glucose indexes in the treatment group were lower than those in the control group, and there were differences between two groups(P < 0.05). After treatment, UAER and α_1-MG levels were significantly decreased in two groups, and there were differences in the same group(P < 0.05). After treatment, UAER and α_1-MG levels in the treatment group were lower than those in the control group, and there were differences between two groups(P < 0.05). After treatment, UA level were significantly decreased in two groups, and there were differences in the same group(P < 0.05). After treatment, UA level in the treatment group were lower than those in the control group, and there were differences between two groups(P < 0.05). Conclusion Salivae Miltiorrhizae Liguspyragine Hydrochloride and Glucose Injection combined with Irbesartan Tablets has significant clinical efficacy in treatment of diabetic nephropathy, can improve blood sugar and renal function, which has a certain clinical application value.
Objective To study the clinical effect of Salivae Miltiorrhizae Liguspyragine Hydrochloride and Glucose Injection combined with Irbesartan Tablets in treatment of diabetic nephropathy. Methods Patients(120 cases) with diabetic nephropathy in the Third People's Hospital of Hainan Province from March 2015 to March 2017 were randomly divided into control group and treatment group, and each group had 60 cases. Patients in the control group were po administered with Irbesartan Tablets, 75 mg/time, twice daily. Patients in the treatment group were iv administered with Salivae Miltiorrhizae Liguspyragine Hydrochloride and Glucose Injection on the basis of the control group, 200 mL/time, once daily. Patients in two groups were treated for 30 d. After treatment, the clinical efficacy was evaluated, and the levels FBG, HbAlc, UAER, α_1-MG, Scr, BUN, and UA in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 88.33% and 96.67%, respectively, and there were differences between two groups(P < 0.05). After treatment, FBG and HbAlc levels were significantly decreased in two groups, and there were differences in the same group(P < 0.05). After treatment, the blood glucose indexes in the treatment group were lower than those in the control group, and there were differences between two groups(P < 0.05). After treatment, UAER and α_1-MG levels were significantly decreased in two groups, and there were differences in the same group(P < 0.05). After treatment, UAER and α_1-MG levels in the treatment group were lower than those in the control group, and there were differences between two groups(P < 0.05). After treatment, UA level were significantly decreased in two groups, and there were differences in the same group(P < 0.05). After treatment, UA level in the treatment group were lower than those in the control group, and there were differences between two groups(P < 0.05). Conclusion Salivae Miltiorrhizae Liguspyragine Hydrochloride and Glucose Injection combined with Irbesartan Tablets has significant clinical efficacy in treatment of diabetic nephropathy, can improve blood sugar and renal function, which has a certain clinical application value.
引文
[1]张建国,丁涵露,任姜汶.糖尿病肾病早期诊治新进展[J].华南国防医学杂志, 2006, 20(2):30-33.
[2]陈芳,吴先明.依那普利、厄贝沙坦与非洛地平对原发性高血压早期肾损害的作用比较[J].中华现代内科学杂志, 2006.
[3]杨雅瑾,蔡德新,黄文辉,等.参芎葡萄糖注射液药理作用及临床应用研究[C].中国药学会第十三届青年药学科研成果交流会论文集.南昌:中国药学会, 2016.
[4]中华中医药学会肾病分会.糖尿病肾病诊断、辨证分型及疗效评定标准(试行方案)[J].上海中医药杂志,2007, 41(7):7-8.
[5]苏映仙.糖尿病肾病的发病机制及治疗新进展[J].糖尿病新世界, 2015(1):56-56.
[6]褚家礼,郭玉岩,王淑玲.参芎葡萄糖注射液治疗糖尿病肾病Ⅲ期的临床观察[J].实用糖尿病杂志,2015,11(4):47-48.
[7]彭祖江.大剂量厄贝沙坦对早期糖尿病肾病微量白蛋白尿的影响[J].山西医药杂志, 2016, 45(2):161-163.
[8]马锦华,刘倩,宋涛.厄贝沙坦治疗早期糖尿病肾病患者的临床研究[J].国际医药卫生导报,2007,13(13):74-76.
[9]李静,西新春.86例患者糖化血红蛋白与血糖检测的相关性研究[J].中国保健营养旬刊, 2012(9):70.
[10]潘秀林,黄定壮,唐国生.尿α1-微球蛋白与血清层粘连蛋白和Ⅳ胶原检测对糖尿病早期肾损伤的预警价值[J].国际检验医学杂志, 2014, 35(12):1631-1633.
[11]徐飞,阮红杰.血清肌酐、尿素氮及尿酸对妊娠期糖尿病肾功能的评价作用[J].蚌埠医学院学报,2015,40(10):1344-1345.
[2]陈芳,吴先明.依那普利、厄贝沙坦与非洛地平对原发性高血压早期肾损害的作用比较[J].中华现代内科学杂志, 2006.
[3]杨雅瑾,蔡德新,黄文辉,等.参芎葡萄糖注射液药理作用及临床应用研究[C].中国药学会第十三届青年药学科研成果交流会论文集.南昌:中国药学会, 2016.
[4]中华中医药学会肾病分会.糖尿病肾病诊断、辨证分型及疗效评定标准(试行方案)[J].上海中医药杂志,2007, 41(7):7-8.
[5]苏映仙.糖尿病肾病的发病机制及治疗新进展[J].糖尿病新世界, 2015(1):56-56.
[6]褚家礼,郭玉岩,王淑玲.参芎葡萄糖注射液治疗糖尿病肾病Ⅲ期的临床观察[J].实用糖尿病杂志,2015,11(4):47-48.
[7]彭祖江.大剂量厄贝沙坦对早期糖尿病肾病微量白蛋白尿的影响[J].山西医药杂志, 2016, 45(2):161-163.
[8]马锦华,刘倩,宋涛.厄贝沙坦治疗早期糖尿病肾病患者的临床研究[J].国际医药卫生导报,2007,13(13):74-76.
[9]李静,西新春.86例患者糖化血红蛋白与血糖检测的相关性研究[J].中国保健营养旬刊, 2012(9):70.
[10]潘秀林,黄定壮,唐国生.尿α1-微球蛋白与血清层粘连蛋白和Ⅳ胶原检测对糖尿病早期肾损伤的预警价值[J].国际检验医学杂志, 2014, 35(12):1631-1633.
[11]徐飞,阮红杰.血清肌酐、尿素氮及尿酸对妊娠期糖尿病肾功能的评价作用[J].蚌埠医学院学报,2015,40(10):1344-1345.